Disclaimer: This is an early beta prototype. If you find any error, with data or functionality, please let us know via this page.
Registration date period
Results ordered by trial registration date, descending.
  1. Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Not recruiting
    Source name:
    ClinicalTrials.gov

    Pathway Genomics Corporation (Pathway Genomics), a San Diego, California company, is involved in the development and validation of new molecular diagnostic assays for the analysis of...

    Conditions:
    • Mutation
    • Neoplasms
    Interventions:
    • ctDNA Analysis for the Detection of Genetic Mutations
  2. Circulating Tumour DNA (ctDNA) Rectal Cancer and the Relationship to Extramural Venous Invasion

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Recruiting
    Source name:
    ClinicalTrials.gov

    In almost one third of patients with rectal cancer, cancer spreads through the bowel wall into nearby veins which can be seen on MRI scans and is known as mrEMVI. It has been observed that...

    Conditions:
    • Rectal cancer
    • Cancer
    Interventions:
    • Blood sample (mrEMVI positive patient)
    • Blood sample (mrEMVI negative patient)
  3. Circulating tumour DNA (ctDNA) analysis informing adjuvant chemotherapy in Stage II Colon Cancer

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Recruiting
    Source name:
    WHO ICTRP

    Conditions:
    • Patients with the diagnosis of Stage II Colon cancer
    • Patients with the diagnosis of stage II rectal cancer
    Interventions:
    • This is a randomized, multi-centre, biomarker driven adjuvant treatment study involving the collection of blood samples from subjects with curatively resected Stage II colon and rectal cancer. 450 consecutive eligible subjects will be enrolled at participating centres after informed consent is obtained. Patients will be enrolled within 28 days post surgery. Subjects will be randomized
    • 1 to be treated according to the ctDNA results (Arm A, n=30
    • , or per standard clinical criteria at the discretion of the treating clinician (Arm B, n=15
    • Resected tumour samples will be made available for mutation analyses. Patients must not have undergone pre-operative chemotherapy or radiotherapy
    • All patients enrolled will have a blood sample taken at enrollment (week
    • and 3 weeks later (week
    • for initial ctDNA testing
    • Patients randomized to Arm A and who have positive ctDNA result will receive adjuvant chemotherapy, patients with negative ctDNA result will not receive chemotherapy
    • Patients randomized to Arm B will be treated at their clinicians discretion. The clinician will initially be blinded to their ctDNA result but results will be provided at or after 6 months post-op following a written request from the site investigator
    • Patients treated with chemotherapy will receive single agent 5FU-based regimen (including capecitabine). Acceptable regimen include:
    • Acceptable 5FU-based chemotherapy regimens include 24 weeks of:
    • 2 weekly De Gramont (modified)
    • a. Leucovorin 50mg IV
    • b. Fluorouracil 400mg/m2 IV
    • c. Fluorouracil 2400mg/m2 CIV pump over 46 hours
    • Weekly modified QUASAR
    • b. Fluorouracil 375-450mg/m2 IV (dose as per institutional standard of care)
    • Weekly modified Roswell Park (weekly for 6 weeks followed by 2 week break)
    • b. Fluorouracil 500mg/m2 IV
    • Capecitabine orally on days 1 to 14 of a 21-day cycle (dose as per institutional standard of care)
    • For patients in Arm A receiving chemotherapy monthly blood samples will be taken to track ctDNA levels
    • Patients in Arm B will have no further blood sampling
    • Patients in all groups will be followed up by data collection for recurrence and overall survival
  4. T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Not recruiting
    Source name:
    ClinicalTrials.gov

    The purpose of this study is to compare the frequency and abundance of T790M mutation among the different Clinical modes of EGFR-TKI failure.

    Conditions:
    • Non-small Cell Lung Cancer Metastatic
    • Non-small cell lung cancer, stage III
    Interventions:
    • ARMS and ddPCR
    • mutation detection
    • ctDNA analysis
  5. Tumor profiling

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Unknown
    Source name:
    EU Clinical Trials Register

    This phase II study is designed to increase the PFS of an anti-tumor drug therapy based on a molecular-biologic tumor profile in patients with proven progressed carcinoma of different origin after all...

    Conditions:
    • Patients with locally advanced and/ or metastasized carcinoma for whom no further evidence-based drug treatment is established.A progression of the tumor is confirmed due to the last evidence-based drug therapy. Due to circulating tumor-DNA (ctDNA) in a blood sample and/or tissue sample of metastasis, a molecular-biologic tumor profiling is performed and an adapted tumor-specific drug therapy is selected
    Interventions:

    Unknown

  6. Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer

    Registration date:
    Status:
    Terminated
    Recruitment status:
    Not recruiting
    Source name:
    ClinicalTrials.gov

    This research trial studies molecular characterization of circulating tumor cells (CTCs) and circulating tumor (ct) deoxyribonucleic acid (DNA) in blood and plasma samples from patients ...

    Conditions:
    • Metastatic Prostate Carcinoma
    • hormone-resistant prostate cancer
    Interventions:
    • laboratory biomarker analysis
    • cytology specimen collection procedure